These intragenic deletions included those targeting known tumour suppressors in glioblastoma such as NF1 (17q11.2, n = 2) (Figure 3a) and RB1 (13q14.2, n = 1) (Additional file 3: Figure S3), as well as putative novel GBM-associated genes including FAF1 (1p33, n = 2) and MTAP (9p21.3, n = 2) (Additional file 3: Figure S3). The gene discussed is NF1; the disease is neoplasm.